Published in Food and Drug Law Weekly, November 5th, 2004
The company anticipates receiving final approval and launching its version of Femhrt in November 2009, 6 months prior to the expiration of the patent on Femhrt, under the terms of the April 2004 agreement between Barr and Warner Chilcott (formerly Galen Holdings PLC). The company plans to market their generic product under the trade name Nevis.
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Food and Drug Law Weekly
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.